-
Hongri Pharmaceutical Co., Ltd. obtains FDA approval for the treatment of sepsis with picrocramide B mesylate for injection
Time of Update: 2021-11-16
In February 2018, it obtained Phase II/III Clinical Approval (Lot No.
After obtaining the US FDA clinical trial qualification this time, KB's phase II clinical research plan for the treatment of patients with sepsis will be carried out in the United States .
-
Many pharmacies who bought and sold pharmacist's certificates were chased for criminal responsibility
Time of Update: 2021-11-16
"According to the information in the indictment, since April 2020, the defendant Yang Moujia (manager of the store management department of a pharmaceutical chain company in Jiaxing City) has collected more than RMB 580,000 for the application of certificates from 68 personnel for the purpose of profit-making.
-
Double the ORR!
Time of Update: 2021-11-16
The data released at the CSCO annual meeting further confirmed that KN046 combined with albumin paclitaxel/gemcitabine has excellent efficacy in the first-line treatment of unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma, and the objective response rate (ORR) is more than doubled compared with traditional chemotherapy.
-
The world's first new crown "oral medicine" will be available. Why is the vaccine, neutralizing antibody, and domestic small molecule oral medicine hit hard?
Time of Update: 2021-11-16
It is reported that among local companies, except Junshi Bio/Lilly's new crown neutralizing antibody drug (JS016), which has been approved for application in many major markets around the world .
-
The first phase Ⅲ clinical study of Kang Ning Jereh double-antibody KN046 completes all patients enrollment
Time of Update: 2021-11-16
ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer for evaluation The safety and effectiveness of KN046 combined chemotherapy at a dose of 5 mg/kg was led by Professor Zhou Caicun from Shanghai Pulmonary Hospital as the main investigator.
-
Merck/Ridgeback oral drug molnupiravir enters rolling review in EU
Time of Update: 2021-11-16
The subjects are included in the laboratory test confirmed as mild to moderate COVID -19 non-hospitalized adult patients (age ≥18 years) who were not vaccinated against SARS-CoV-2, had at least one risk factor related to adverse disease outcome, and developed symptoms within 5 days before randomization .
-
Junshi Biology JS019 Injection Obtained the Notification of Acceptance of Drug Clinical Trial Application
Time of Update: 2021-11-16
(hereinafter referred to as " Suzhou Keboruijun") received the "Notice of Acceptance" approved and issued by the State Drug Administration, and the clinical trial application for JS019 injection (project code "JS019") was accepted .
-
Changes in the treatment of nAMD!
Time of Update: 2021-11-16
On October 22, Roche announced that the FDA has approved its new drug delivery device Susvimo (Ranibizumab injection 100mg/ml) for the treatment of at least two anti-VEGF therapies for wet age-related macular degeneration (nAMD).
-
The official topping of the Lvgu sugar drug production base is expected to benefit Alzheimer's patients worldwide
Time of Update: 2021-11-16
It is committed to ensuring production quality and In line with international standards, as China's first production base for exporting sugar drugs to the world, it carries the important mission of the internationalization of China's original drugs, which is expected to benefit patients with Alzheimer's disease (AD) worldwide .
-
BeiGene's BTK-targeted protein degrading agent is accepted for clinical application in China
Time of Update: 2021-11-16
▲CDAC platform of BeiGene (Source: BeiGene Public PPT)Public information shows that BGB-16673 is a protein degradation agent targeting Bruton's tyrosine kinase (BTK) .
-
Big moves continue!
Time of Update: 2021-11-16
On October 10th, Zhang Lianshan, Senior Deputy General Manager and President of Global R&D of Hengrui Pharmaceuticals, stated at the 2021 Biopharmaceutical Process Development Summit BPD that China’s innovative drugs are an inevitable choice to “go global” .
-
Pioneer Pharmaceuticals completes the first patient administration in the Phase III clinical trial of Prokalutamide in the treatment of hospitalized patients with new crowns in the United States
Time of Update: 2021-11-16
Tong Youzhi, Founder, Chairman and CEO of Pioneer Pharmaceuticals, said: "I am very pleased to announce that the registered Phase III clinical trial of Prokalamide for the treatment of hospitalized patients with severe new coronary disease has completed the first patient enrollment in the United States .
-
"Nobel Prize in Medicine"-Galen Prize will be announced soon!
Time of Update: 2021-11-16
There are three main awards for the Galen Award: Best Pharmaceutical Agent, Best Biotechnology Product, and Best Medical Technology .
In 2012 and 2014, the Galen Prize was awarded to hepatitis C treatment drugs .
-
Pioglitazone Hydrochloride Tablets, a wholly-owned subsidiary of Kangen Bay, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-16
On October 20, Kang Enbei issued an announcement stating that its wholly-owned subsidiary Hangzhou Kang Enbei received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and pioglitazone hydrochloride tablets passed the consistency evaluation of generic drugs .
-
Is the new crown vaccine not "red" anymore?
Time of Update: 2021-11-16
Unlike the cooperation between Tibet Pharmaceuticals and Sri Lanka Microbiology, the new coronavirus vaccine (PIV-5 carrier) licensing cooperation agreement of Changchun High-tech, Beike Biotech and Guangzhou Sianxin Biotech is a connected transaction .
-
Many provinces announced: cancel this year's licensed pharmacist exam
Time of Update: 2021-11-16
According to the relevant requirements of the Hunan Provincial Department of Epidemic Prevention and Control and the relevant regulations of Hunan Personnel Examination and Epidemic Prevention and Control, people with a history of residence in the following areas are not allowed to go to the test site to participate in the public recruitment examination of public institutions in Hunan Province on October 23, 2021 and Hunan Province’s 2021 survey Qualification examination for design, urban and rural planners, licensed pharmacists:1.
-
Helixangyuan sincerely invites customers and partners to participate in the 61st Chengdu Pharmaceutical Machinery Exhibition in 2021
Time of Update: 2021-11-16
Beijing, October 14, 2021/PRNewswire/ - Helixangyuan will participate in the 61st (Autumn 2021) National Pharmaceutical Machinery Expo in Chengdu, Sichuan on November 2-4, 2021.
-
Microchip's new diabetes drug sitaglipta sodium is approved for listing in China
Time of Update: 2021-11-16
According to the NMPA official website, as a new PPAR full agonist, sitaglipta sodium can not only control blood sugar in the treatment of type 2 diabetes, but also treat the lipid and energy metabolism disorders that are usually associated with patients, thereby benefiting the heart.
-
In-depth analysis of Hengrui's innovative drug design case to explore the golden road of "Yao Mao"
Time of Update: 2021-11-16
In the patent published in 2021 (CN 113004303), a class of pyrimidooxazine tricyclic derivatives are mentioned as ATR kinase inhibitors; Hengrui followed AZD-6738.
In another ATR inhibitor patent of Hengrui (CN 113135942 A), the best possible compound 3 is obtained from AZD-6738 backbone transition, isosteric, and ring closure.
-
Guhan Biology, a wholly-owned subsidiary of Tus Pharmaceuticals, and Tus Guhan Industrial Park completed the deregistration
Time of Update: 2021-11-16
Subsidiaries "Hunan Guhan Biological Technology Co.
The company recently received the notice of approval to cancel the registration of the above two subsidiaries issued by the Hengyang Market Supervision Administration .
The deregistration procedures for "Hunan Guhan Biological Technology Co.
